The effects of CRF and urocortins on the hippocampal glutamate release

Zsolt Bagosi, Beáta Balangó, Dávid Pintér, Krisztina Csabafi, M. Jászberényi, Gyula Szabó, G. Telegdy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Corticotropin-releasing factor (CRF) is a hypothalamic neurohormone and an extrahypothalamic neurotransmitter that regulates the hypothalamic-pituitary-adrenal (HPA) axis. The urocortins (UCN I, UCN II and UCN III) are CRF-related peptides, which may also regulate the HPA axis directly or indirectly, by modulation of extrahypothalamic neurotransmitters, such as amygdalar GABA and hippocampal glutamate. Our previous in vitro superfusion studies have already demonstrated that CRF and UCN I stimulate the amygdalar GABA release in rats. The aim of the present study was to investigate the effects of CRF, UCN I, UCN II and UCN III on the glutamate release elicited electrically from rat hippocampal slices in similar in vitro conditions. In order to investigate the participation of CRF receptors (CRFR1 and CRFR2) in this process, hippocampal slices were pretreated with antalarmin, a selective antagonist of CRFR1 or astressin 2B, a selective antagonist of CRFR2. CRF and UCN I at 100 nM decreased significantly the hippocampal glutamate release evoked by electrical stimulation. In contrast, 100 nM of UCN II and UCN III did not affect significantly the hippocampal glutamate release enhanced by electrical stimulation. The decreasing effects of CRF and UCN I were reversed by antalarmin, but not by astressin 2B, both being administered in equimolar doses. Our results demonstrate that CRF and UCN I inhibit the glutamate release in the hippocampus via CRFR1 and that CRFR2 does not participate to this process. Based on the previous and the present results we conclude that CRFR1 agonists can activate the HPA axis not only directly, but also indirectly by increasing the amygdalar GABA release and decreasing the hippocampal glutamate release.

Original languageEnglish
Pages (from-to)67-71
Number of pages5
JournalNeurochemistry International
Volume90
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Urocortins
Corticotropin-Releasing Hormone
Glutamic Acid
gamma-Aminobutyric Acid
Neurotransmitter Agents
Electric Stimulation
Corticotropin-Releasing Hormone Receptors
Hippocampus
Peptides

Keywords

  • CRF
  • Glutamate
  • HPA axis
  • Superfusion
  • Urocortin

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

The effects of CRF and urocortins on the hippocampal glutamate release. / Bagosi, Zsolt; Balangó, Beáta; Pintér, Dávid; Csabafi, Krisztina; Jászberényi, M.; Szabó, Gyula; Telegdy, G.

In: Neurochemistry International, Vol. 90, 01.11.2015, p. 67-71.

Research output: Contribution to journalArticle

Bagosi, Zsolt ; Balangó, Beáta ; Pintér, Dávid ; Csabafi, Krisztina ; Jászberényi, M. ; Szabó, Gyula ; Telegdy, G. / The effects of CRF and urocortins on the hippocampal glutamate release. In: Neurochemistry International. 2015 ; Vol. 90. pp. 67-71.
@article{dd877607331c44069822437183614365,
title = "The effects of CRF and urocortins on the hippocampal glutamate release",
abstract = "Corticotropin-releasing factor (CRF) is a hypothalamic neurohormone and an extrahypothalamic neurotransmitter that regulates the hypothalamic-pituitary-adrenal (HPA) axis. The urocortins (UCN I, UCN II and UCN III) are CRF-related peptides, which may also regulate the HPA axis directly or indirectly, by modulation of extrahypothalamic neurotransmitters, such as amygdalar GABA and hippocampal glutamate. Our previous in vitro superfusion studies have already demonstrated that CRF and UCN I stimulate the amygdalar GABA release in rats. The aim of the present study was to investigate the effects of CRF, UCN I, UCN II and UCN III on the glutamate release elicited electrically from rat hippocampal slices in similar in vitro conditions. In order to investigate the participation of CRF receptors (CRFR1 and CRFR2) in this process, hippocampal slices were pretreated with antalarmin, a selective antagonist of CRFR1 or astressin 2B, a selective antagonist of CRFR2. CRF and UCN I at 100 nM decreased significantly the hippocampal glutamate release evoked by electrical stimulation. In contrast, 100 nM of UCN II and UCN III did not affect significantly the hippocampal glutamate release enhanced by electrical stimulation. The decreasing effects of CRF and UCN I were reversed by antalarmin, but not by astressin 2B, both being administered in equimolar doses. Our results demonstrate that CRF and UCN I inhibit the glutamate release in the hippocampus via CRFR1 and that CRFR2 does not participate to this process. Based on the previous and the present results we conclude that CRFR1 agonists can activate the HPA axis not only directly, but also indirectly by increasing the amygdalar GABA release and decreasing the hippocampal glutamate release.",
keywords = "CRF, Glutamate, HPA axis, Superfusion, Urocortin",
author = "Zsolt Bagosi and Be{\'a}ta Balang{\'o} and D{\'a}vid Pint{\'e}r and Krisztina Csabafi and M. J{\'a}szber{\'e}nyi and Gyula Szab{\'o} and G. Telegdy",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.neuint.2015.07.015",
language = "English",
volume = "90",
pages = "67--71",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - The effects of CRF and urocortins on the hippocampal glutamate release

AU - Bagosi, Zsolt

AU - Balangó, Beáta

AU - Pintér, Dávid

AU - Csabafi, Krisztina

AU - Jászberényi, M.

AU - Szabó, Gyula

AU - Telegdy, G.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Corticotropin-releasing factor (CRF) is a hypothalamic neurohormone and an extrahypothalamic neurotransmitter that regulates the hypothalamic-pituitary-adrenal (HPA) axis. The urocortins (UCN I, UCN II and UCN III) are CRF-related peptides, which may also regulate the HPA axis directly or indirectly, by modulation of extrahypothalamic neurotransmitters, such as amygdalar GABA and hippocampal glutamate. Our previous in vitro superfusion studies have already demonstrated that CRF and UCN I stimulate the amygdalar GABA release in rats. The aim of the present study was to investigate the effects of CRF, UCN I, UCN II and UCN III on the glutamate release elicited electrically from rat hippocampal slices in similar in vitro conditions. In order to investigate the participation of CRF receptors (CRFR1 and CRFR2) in this process, hippocampal slices were pretreated with antalarmin, a selective antagonist of CRFR1 or astressin 2B, a selective antagonist of CRFR2. CRF and UCN I at 100 nM decreased significantly the hippocampal glutamate release evoked by electrical stimulation. In contrast, 100 nM of UCN II and UCN III did not affect significantly the hippocampal glutamate release enhanced by electrical stimulation. The decreasing effects of CRF and UCN I were reversed by antalarmin, but not by astressin 2B, both being administered in equimolar doses. Our results demonstrate that CRF and UCN I inhibit the glutamate release in the hippocampus via CRFR1 and that CRFR2 does not participate to this process. Based on the previous and the present results we conclude that CRFR1 agonists can activate the HPA axis not only directly, but also indirectly by increasing the amygdalar GABA release and decreasing the hippocampal glutamate release.

AB - Corticotropin-releasing factor (CRF) is a hypothalamic neurohormone and an extrahypothalamic neurotransmitter that regulates the hypothalamic-pituitary-adrenal (HPA) axis. The urocortins (UCN I, UCN II and UCN III) are CRF-related peptides, which may also regulate the HPA axis directly or indirectly, by modulation of extrahypothalamic neurotransmitters, such as amygdalar GABA and hippocampal glutamate. Our previous in vitro superfusion studies have already demonstrated that CRF and UCN I stimulate the amygdalar GABA release in rats. The aim of the present study was to investigate the effects of CRF, UCN I, UCN II and UCN III on the glutamate release elicited electrically from rat hippocampal slices in similar in vitro conditions. In order to investigate the participation of CRF receptors (CRFR1 and CRFR2) in this process, hippocampal slices were pretreated with antalarmin, a selective antagonist of CRFR1 or astressin 2B, a selective antagonist of CRFR2. CRF and UCN I at 100 nM decreased significantly the hippocampal glutamate release evoked by electrical stimulation. In contrast, 100 nM of UCN II and UCN III did not affect significantly the hippocampal glutamate release enhanced by electrical stimulation. The decreasing effects of CRF and UCN I were reversed by antalarmin, but not by astressin 2B, both being administered in equimolar doses. Our results demonstrate that CRF and UCN I inhibit the glutamate release in the hippocampus via CRFR1 and that CRFR2 does not participate to this process. Based on the previous and the present results we conclude that CRFR1 agonists can activate the HPA axis not only directly, but also indirectly by increasing the amygdalar GABA release and decreasing the hippocampal glutamate release.

KW - CRF

KW - Glutamate

KW - HPA axis

KW - Superfusion

KW - Urocortin

UR - http://www.scopus.com/inward/record.url?scp=84947027571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947027571&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2015.07.015

DO - 10.1016/j.neuint.2015.07.015

M3 - Article

VL - 90

SP - 67

EP - 71

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

ER -